SCI Abstract

search
+
Persistence of M-proteins detected by mass spectrometry
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undeterm...
Lenalidomide and rituximab for relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
Lenalidomide (len) and rituximab (R2) is standard second-line therapy for follicular lymphoma (FL), and the backbone and c...
Immune effector cell associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy is highly effective in relapsed/r...
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
Bispecific antibodies (bsAbs) targeting B-cell maturation antigen (BCMA) and G protein–couple...
Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification
Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification
Several limitations should be acknowledged. This was a retrospective single-center study conducted across multiple treatme...
Infection burden among patients with triple-class–exposed RRMM receiving non–T-cell–redirecting therapies: a US claims study
Triple-class–exposed (TCE) relapsed/refractory multiple myeloma (RRMM) is associated with cumulative immunosuppressi...
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
These authors contributed equally: Doris K. Hansen, Danai Dima, Hira Mian.These authors jointly supervised this work: Surb...
A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma
A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma
Competing interests RA reports travel support from Amgen, Sanofi, BeOne an...
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data
Transcriptomic profiles from 92 patients with FLT3ITD were compared to those of 335 patients with FLT3WT AML. Principal co...
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in...
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the trea...
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience
Competing interests DB: declares no conflicts of interest. PJH: Research f...
First-line treatment for CLL in the era of targeted therapy
In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the tre...
Is Less “Sufficient” and “Safe” in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma
Is Less “Sufficient” and “Safe” in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma
This was a retrospective single-centre study from India, which included MM patients who underwent ASCT over the last 15 ye...
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy
Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibili...
NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance
NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characteri...
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia
Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia
Somatic mutations in genes encoding isocitrate dehydrogenase (IDH) enzymes a...
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
Competing interests Parrondo serves on the advisory board for Sanofi Avent...
Poor prognostic implication of CDKN2 deletion in adult patients with Philadelphia chromosome-positive ALL
Poor prognostic implication of CDKN2 deletion in adult patients with Philadelphia chromosome-positive ALL
Advancements in tyrosine kinase inhibitors [1], novel agents such as blinatumomab [2], and allogeneic hematopoietic cell t...
Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
The treatment landscape of multiple myeloma (MM) has evolved significantly over four decades, driven by novel therapies an...
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies
While observation is the current standard of care for smoldering multiple myeloma (sMM), emerging evidence suggests that e...
Correction: Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4....
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis
Survey of interpretation practices of unbalanced MYC break-apart resultsFifty-four responses were obtained to the survey q...
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Competing interests EM and VG have no conflicts of interest to disclose. S...
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Myelodysplastic neoplasms (MDS) are hematopoietic stem cell (HSC) disorders arising in the bone marro...
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
Nucleophosmin 1 (NPM1) is one of the most frequently mutated genes (~30% of cases) in acute myeloid l...
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia
Inequitable uptake of novel therapies (NT) in non-cancer settings are known for patients with lower socioeconomic status (...
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma primari...
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III–IV diffuse large...
Load More
format_indent_increase